Rank #1594SRPT

Sarepta Therapeutics, Inc.

$18.59

1.14% (Daily)

Market Cap

$1.95B

Revenue

$2.41B

Rank by MCap

#1594

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Douglas S. Ingram Esq., J.D.

Headquarters

Cambridge, MA

Employees

1,372

About Sarepta Therapeutics, Inc.

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat Duchenne muscular dystrophy (Duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients with confirmed mutation of the...